comorbidities for glp 1 Exploring GLP-1 prescriptions and comorbidites Body-wide multi-omic counteraction of aging

1 The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsA Long-Term Evaluation), a large double-blind, placebo-controlled trial, recently demonstrated that liraglutide added to standard therapy for a relatively short period of time (3.5-5 years) had a significant reduction in cardiovas-cular events and mortality compared to placebo in high-risk patients (hazard ratio [HR], 0.87

Glucagon-like peptide-1 (GLP-1) is considered an ideal drug for the treatment of type 2 diabetes mellitus (T2DM)

More than 40 million people worldwide live with AF, and in the United States alone, approximately 454,000 hospitalizations each year are associated with the condition

Finally, maximizing digestion is imperative to the first two objectives while also ensuring we are able to extract maximum nutrition from the food we eat

Lactobacillus acidophilus , which can secrete antimicrobial substances and suppress pro-inflammatory cytokines including TNF-, IL-1, IL-6, and PGE2 ( Akkermansia and Lactobacillus (Zeng et al., 2024), which are known to enhance gut barrier function and suppress inflammation

Supplies Needed Plan based on an 816 week stacked protocol with standard dosing (CJC-1295 DAC 1 mg/week + Ipamorelin 200 mcg/day at maintenance)